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Abstract
Background Transgender women have 49 times the odds of
human immunodeficiency virus (HIV) infection compared to
other groups, yet they are disproportionately underserved by
current treatment efforts.
Purpose This study aimed to examine culturally unique barriers
and facilitators to engagement and retention in HIV care and
strengthen efforts to mitigate health disparities, guided by the
Models of Gender Affirmation and Health Care Empowerment.
Methods Through 20 interviews and five focus groups (n=38),
transgender women living with HIV discussed their experiences
and life contexts of engagement in and adherence to HIV care
and treatment.
Results Our participants faced substantial challenges to ad-
hering to HIV care and treatment, including avoidance of
healthcare due to stigma and past negative experiences, prior-
itization of hormone therapy, and concerns about adverse
interactions between antiretroviral treatment for HIVand hor-
mone therapy. Receiving culturally competent, transgender-
sensitive healthcare was a powerful facilitator of healthcare
empowerment.
Conclusions Recommendations are offered to inform interven-
tion research and guide providers, emphasizing gender affirming
HIV care that integrates transition-related healthcare needs.
Keywords HIV care . Transgender women . Engagement .
Retention . Adherence
Transgender women are one of the most highly impacted
groups in the human immunodeficiency virus (HIV) epidemic
to date, yet they are disproportionately under-researched and
underserved by current treatment efforts. Transgender women
have 49 times higher odds of HIV infection compared to other
groups, a disparity that exists across race, culture, and socio-
economic boundaries [1]. Disparate prevalence rates of HIV
are particularly pronounced for African-American transgender
women when compared with transgender women of other
races and ethnicities [2].
In addition, there is evidence that current efforts to provide
effective treatment to transgender women living with HIVare
not as successful as with other populations. The importance of
early initiation of antiretroviral therapy and optimal adherence
to promote health and reduce transmission is widely recog-
nized [3, 4]. Active engagement in clinical care and high
levels of adherence to antiretroviral therapy are critical to
allow people with HIV to live longer, healthier lives. Howev-
er, in the only study of its kind to date, transgender women
living with HIV were less likely to be receiving antiretroviral
therapy than a control group of non-transgender men and
women [5]. Furthermore, transgender women living with
HIV who were on antiretroviral therapy demonstrated worse
adherence than non-transgender people, reported less confi-
dence in their abilities to integrate treatment regimens into
their daily lives, and had fewer positive interactions with their
healthcare providers [6]. From a public health perspective,
HIV+ transgender women have an almost threefold higher
viral load than non-transgender HIV+ adults in San Francisco
(64,160 vs. 22,376) [7] and likely elsewhere. HIV-related
mortality and morbidity rates have also been found to be
higher among transgender women [8]. These findings warrant
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investigation of the barriers to treatment among transgender
women.
The cascade of missed opportunities for treatment begins
with lack of HIV testing and moves to lack of linkage to care,
poor retention in care, and low initiation and adherence to
antiretroviral therapy [9]. It is likely that the factors that put
transgender women at heightened risk for HIV infection also
increase the risk of treatment failure at each of the points along
this continuum. Giordano and colleagues documented that
inconsistent engagement and retention in care (as measured
by appointment keeping over time) were associated with
increased morbidity among a large cohort of HIV+ adults
[10], as those with low CD4 counts not on treatment represent
an at-risk population for AIDS-related illness and death.
Marginalized populations such as transgender women, ra-
cial and ethnic minorities, substance abusers, those with men-
tal illness, and those with unstable housing are more adversely
impacted by the challenges associated with accessing and
adhering to care [11–13]. These factors can result in late
presentation (or no presentation) to HIV medical care and
can consequently lead to poorer health outcomes than if they
had sought care earlier in the disease process [14]. Adherence
to antiretroviral therapy can be difficult due to factors such as
the complexity of the regimens, side effects, HIV-related
stigma, and competing priorities and demands [15]. However,
disparities exist along social, economic, gender, and racial/
ethnic lines, and there is evidence that some providers do not
offer antiretroviral therapy to members of certain groups, such
as racial and ethnic minorities, due to preconceptions that they
would be less adherent [16, 17].
In addition to the health outcomes of the individual patient
who has not initiated appropriate pharmacologic treatment,
there are substantial associated public health outcomes. Trans-
gender women who are not on antiretroviral therapy (or if on
antiretroviral therapy, not adherent) are at increased risk for
transmission of HIV to others. This heightened risk for new
infections may result from risk factors demonstrated to be at
higher prevalence in this population, including substance use,
high number of sex partners, and trading sex for money, drugs,
and shelter [18–20]. Second, those not on antiretroviral ther-
apy or who are not adherent are likely to be more infectious
due to uncontrolled viral load than those whose virus is
controlled by antiretroviral therapy, thus multiplying the risk
of transmitting HIV to uninfected individuals. Understanding
patterns of HIV healthcare utilization, including treatment
refusal, ambivalence, and/or low adherence rates in addition
to facilitators to engagement in care among transgender wom-
en living with HIV may lead to different strategies to help
patients make more informed treatment decisions and to im-
prove health outcomes.
Due to the disproportionate burden of HIVon transgender
women of color (particularly African-American transgender
women), it is important to frame this area of inquiry with an
intersectional perspective. Intersectionality research considers
the escalatory effect of multiple inequalities experienced by
marginalized groups [21]. This framework posits that social
inequalities are the result of the intersection of differences
related to race, class, gender, etc. Transgender women of color
are likely to experience multiplicative effects of marginalized
social identities, with evidence that African-American trans-
gender women are particularly vulnerable to experiencing
social marginalization and its negative consequences [22].
For example, African-American transgender women are more
likely to report a history of incarceration [23], homelessness
[22], being uninsured [22], experiencing discrimination [24],
engagement in sex work [22, 25], and are less likely to be
employed full time than other transgender women [26]. Iden-
tities may intersect in ways that support positive outcomes as
well. For example, African-American transgender women
may also be more likely to report having a spiritual practice
that may promote resilience [27, 28]. In this study, we con-
sidered the impact of intersecting identities on participants'
experiences seeking and adhering to HIV care and treatment.
Theoretical Framework
In developing this study, we approached the topic from a
perspective informed by the Models of Gender Affirmation
and Health Care Empowerment. The Model of Gender Affir-
mation is a transgender-specific theoretical model developed
to examine the role of gender affirmation in risk-taking, self-
care, and healthcare-seeking behavior [29]. “Gender affirma-
tion” is the process by which individuals feel socially validat-
ed in their gender identity through interpersonal interactions,
such as interactions with a healthcare provider. A gender
affirming healthcare experience would include, for example,
a transgender patient being called by the correct name and
pronoun by all staff throughout the healthcare encounter with-
out unnecessary attention being drawn to her transition status.
The Model of Gender Affirmation posits that when a trans-
gender woman's need for gender affirmation is high but her
access to this type of affirmation is low, she will seek out
opportunities to receive this affirmation, sometimes in ways
that might pose risks to her health, such as having sex to affirm
her femininity [29, 30]. The model accounts for the role that
psychosocial factors play in transgender women's need for and
access to gender affirmation. For example, transphobia, or the
stigma associated with being transgender, can be experienced
as enacted by other people and it can also be internalized.
Experienced (or “enacted”) transphobia limits transgender
women's access to gender affirmation while internalized
transphobia increases the need for gender affirmation. Simi-
larly, other psychosocial factors, especially experiences of
trauma, and varying levels of social support, life stability,
and substance use can all affect transgender women's access
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to and need for gender affirmation. The Model of Health Care
Empowerment posits that vulnerable populations will experi-
ence improved health outcomes through engagement and
retention in HIV care when they are informed, committed,
collaborative, and engaged in their healthcare [31–33]. We
were interested in how, taken together, these models create a
conceptual framework for the examination of factors that
affect engagement in healthcare from a transgender-specific
perspective.
The aim of this study was to examine the barriers and
facilitators that may be unique to transgender women in order
to elucidate the observed disparities in engagement and reten-
tion in HIV care. Through this examination, we hope to
provide insight and guidance to those wishing to better engage
and serve this population and contribute to efforts to under-
stand and mitigate the forces that result in disproportionately
poor health outcomes.
Methods
This study explored HIV+ transgender women's experiences,
perspectives, and life contexts of engagement and retention in
HIV treatment and antiretroviral therapy initiation and adher-
ence through focus groups and in-depth individual interviews.
Including both individual interviews and focus groups with
HIV+ transgender women was important to obtain depth and
breadth of content. Individual interviews reduce participant
concern about peer acceptance and confidentiality, which
results in detailed content and context to the data acquired.
Focus groups foster broader topic exploration through group
members' exchange of ideas and responses, opening the pos-
sibility for dialogue and debate among different members of
the group. Focus group discussions are especially well suited
to the assessment of inter-subjective cultural norms within
groups [34]. Through these combined approaches, we aimed
to gain a thorough understanding of individual, social, and
contextual issues associated with HIV treatment engagement
and adherence.
Participants
Participants for the focus groups and individual interviews
were purposively sampled based on HIV status from a cross-
sectional survey of transgender women in the San Francisco
Bay Area; snowball sampling and street-based recruitment
were also used. Community-based agencies that serve trans-
gender women also assisted with recruitment by posting flyers
in their common spaces. Eligibility criteria were assigned
“male” gender at birth and currently identifies as “female” or
“transgender” or some variation indicating the person does not
identify with her birth sex (i.e., transsexual, gender variant,
male-to-female, MTF, etc.), 18 years of age or older, currently
living with HIV (by self-report), and able to provide informed
consent.
Procedures
The Models of Gender Affirmation and Health Care Empow-
erment served as our conceptual framework, guiding the study
design and analysis [35]. The interview and focus group
guides were shaped by this conceptual framework through
its use as a starting point for generating questions that ex-
plored how needs for transgender-specific healthcare and
gender affirmation might facilitate or hinder engagement and
empowerment in healthcare.
Individual Interviews
The individual interviews (N =20) focused on experiences of
HIV testing and first learning of HIV+ diagnosis, social sup-
port around their diagnosis, accessing treatment, treatment
regimens, experiences of and concerns about adverse side
effects, access to and relationships with providers, issues and
concerns around treatment, adherence, and retention in care.
Questions focused on transgender-specific aspects of
healthcare-seeking behavior, including questions about as-
pects of healthcare-seeking behavior that pertain to the role
of gender affirmation, such as seeking transition-related
healthcare, and on how informed, committed, collaborative,
and engaged the participant was in her own healthcare. Sam-
ple items from the individual interview guide include “Tell me
about when you tested positive for HIV” and “Tell me about
your most recent visit to a doctor for HIV related reasons.”
Sample questions related to hormone use included: “Are you
currently seeing a doctor for your hormones? How do you feel
about him/her?” Two trained interviewers conducted the in-
depth individual interviews; both are male, one is transgender
and one is non-transgender. Participants were informed that
they were being asked to participate because they are a trans-
gender woman living with HIV and that the study was being
conducted to help us learn more about ways to increase HIV+
transgender women's access to HIV treatment and help them
adhere to their treatment. Interviews lasted approximately 1–
1.5 h on average. Participants were compensated US$40 for
their time.
Focus Groups
We conducted five focus groups (n =38) with transgender
women living with HIV in the San Francisco Bay Area. Focus
group guides elicited content related to experiences seeking or
avoiding healthcare (e.g., HIV-related care, gender-related
healthcare, mental healthcare, substance abuse treatment,
etc.), housing, food, experiences of and challenges with
accessing, engaging, and adhering to HIV care, and other
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content related to services. Sample questions from the focus
group guide include “Have you received any type of HIV-
related medical care? If so, what has been your experience
with this care?” and “What do you see as the biggest obstacles
to getting the services you need?” Four focus groups were
held in English (n =33) and one in Spanish (n =5); two trans-
gender women of color extensively trained in focus group
facilitation led both groups. Participants were informed that
we were interested in learning about the health service needs
and experiences of transgender women living with HIV. Focus
groups lasted approximately 1.5 h on average. Participants
were compensated US$30 for their time. All procedures were
approved by the UCSF Committee on Human Research.
Data Analysis
Interviews and focus groups were digitally recorded, tran-
scribed verbatim (the Spanish focus group transcript was
professionally translated prior to analysis), and entered into
Atlas.ti software for data management and analysis. Tran-
scripts were analyzed using template analysis, a standard
qualitative technique for identifying and organizing themes
through the development of a coding template [36]. In this
case, the a priori themes were based on the primary research
question, that is, “what are the unique barriers and facilitators
of engagement and retention in HIV care faced by transgender
women living with HIV?” Initial coding of the data consisted
of reading the transcripts and identifying sections of the text
that correspond to the a priori themes. Each interview was
read and analyzed by two teammembers, one primary (second
author) and one secondary (first author). The primary analyst
coded each interview using the thematic codes developed
based on the apriori themes. Then, the secondary analyst read
each coded interview while inserting additional codes and
commentary to contribute a dissenting viewpoint or expand
the interpretation of the primary analyst. While this technique
allowed both coders to confirm the accuracy and interpretation
of themes, it precluded the use of a quantitative measure of
interrater reliability due to the potential for over-inflation of
the estimate [37]. Any differential use of codes or interpreta-
tion of data was resolved through discussion. No major dif-
ferential interpretations were noted, indicating a high level of
agreement between coders. As the data highlighted issues that
were not included among the a priori themes, existing themes
were modified or a new theme was created in an iterative
process. Once all interviews were discussed and coded, we
conducted searches as relevant to our analysis. We searched
single codes across the data set or subset to compile all of the
passages associated with this code, an analytical approach that
identifies patterns of experience and permits comparisons of
the experiences of different participants. We also searched for
the overlap of multiple codes, which identifies associations
between different themes. Final analysis and interpretation
was guided by the Models of Gender Affirmation and Health
Care Empowerment and organized thematically [9].
Results
Participants
Participant characteristics are listed in Table 1. Participants in
both the individual interviews and the focus group were
predominantly African-American (85 and 71%, respectively).
Latinas and Native Americans were relatively well represent-
ed in the focus groups (18 and 11 %) but were not represented
among the individual interview participants. The majority of
both individual interview and focus groups participants were
between the ages of 40 and 59, had some college, and en-
dorsed the statement “I barely have enough money to get by”
when asked about their current financial situation. Additional
information was collected from individual interview partici-
pants about HIV and hormone therapy care and treatment
status as well as self-reported adherence to both hormones
and antiretroviral therapy. All individual interview partici-
pants reported that they were receiving some type of HIV care
at the time of the interview.
Thematic Findings
To provide consistency in the use of qualitative terms, findings
are presented by indicating the proportion of participants who
discussed each theme according to the following classification
system: “none” 0 %; “a few” 1–20 %; “some” 21–40 %;
“about half” 41–60 %; “many” 61–80 %; “almost all” 81–
99 %; and “all” 100 % [38].
Gender Affirming Healthcare Is Critically Important
to Engagement and Retention
Gender Affirmation in HIV Testing and Care Settings
Participants stressed the importance of gender affirming
healthcare at all stages of the HIV continuum of care, from
testing to full engagement in care. The cultural competency of
the provider was described as extremely important to engage-
ment and retention by all participants. About half of the
participants also mentioned the clinic environment and staff,
emphasizing that both should be welcoming to and respectful
of transgender patients. Gender affirming healthcare meant
that providers were knowledgeable about trans-related medi-
cal issues, ideally able to provide and integrate both hormone
therapy and HIV care, and all staff members were respectful
and sensitive to issues that may be difficult for transgender
patients. Focus group participants reported that they were
reassured about seeking care when they received referrals
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from other transgender women who reported positive experi-
ences at certain clinics or from trans-specific agencies who
endorsed certain providers.
“It's how the doctors—it's about respect and it's about
the knowledge that they have, and it's about sensitivity.”
(African-American interview participant, age 54)
Some participants reported that before they received their
diagnosis, they avoided HIV testing sites because they were
perceived as not trans-friendly. In particular, HIV testing sites
that serve gay men were generally not perceived as transgen-
der friendly or sensitive. Participants described resentment
that they continue to be classified as men who have sex with
men and refused to engage in services that were not respectful
or inclusive of their gender identity. When testing sites ac-
quired reputations as not being sensitive to transgender wom-
en, participants reported that word spread quickly and they
would avoid those sites.
“[A local HIV testing agency] serves gay men…They
might think they are for me too but they are not for me…
I am not a man. I don't want to be treated like one.”
(Focus group participant)
Some participants reported that when they were first diag-
nosed, they similarly avoided seeking medical care due to past
negative experiences and transphobia. They reported that they
were reluctant to access services where they were not sure
whether the providers would be familiar with treating trans-
gender people, and they worried about having to deal with
clinic staff that might be transphobic or refuse to use the
correct name or pronoun. For instance, many transgender
Table 1 Participant demographics
Individual
interviews,
N (%)
Focus group
participants,
N (%)
Total,
N (%)
Race/ethnicitya
African-American/Black 17 (85) 27 (71) 44 (76)
Latina 0 (0) 7 (18) 7 (12)
Pacific Islander 1 (5) 3 (8) 4 (7)
Native American 0 (0) 4 (11) 4 (7)
Multiracial 1 (5) 3 (8) 4 (7)
Caucasian 1 (5) 3 (8) 4 (7)
Other 0 (0) 1 (3) 1 (2)
Age
20–29 0 1 (3) 1 (2)
30–39 2 (10) 7 (18) 9 (16)
40–49 7 (35) 10 (26) 17 (29)
50–59 10 (50) 18 (47) 28 (48)
60–69 1 (5) 1 (3) 2 (3)
Did not respond 0 (0) 1 (3) 1 (2)
Educational level
Some high school 3 (15) 13 (35) 16 (28)
High school diploma or general
educational development
5 (25) 3 (8) 8 (14)
Technical or vocational school 0 (0) 2 (5) 2 (3)
Some college 10 (50) 18 (49) 28 (48)
College degree 2 (10) 1 (3) 3 (5)
Did not respond 0 (0) 1 (3) 1 (2)
Financial situation
I do not have enough money to
get by
3 (15) 7 (20) 10 (17)
I barely have enough money to
get by
13 (65) 19 (54) 32 (55)
I have money to get by 4 (20) 9 (26) 13 (22)
Did not respond 0 (0) 3 (8) 3 (5)
Human immunodeficiency virus treatment status
Currently on antiretroviral
therapy
16 (80)
Previously but not currently 0 (0)
Never on antiretroviral therapy 4 (20)
Self-reported adherence to antiretroviral therapy
Excellent 5 (25)
Very good 6 (30)
Good 3 (15)
Fair 2 (10)
Poor 0 (0)
Very poor 0 (0)
Not applicable 4 (20)
Self-reported viral load
Undetectable 14 (70)
Detectable 5 (25)
Do not know 1 (5)
Hormone treatment status
Currently on hormones 15 (75)
Table 1 (continued)
Individual
interviews,
N (%)
Focus group
participants,
N (%)
Total,
N (%)
Previously but not currently on
hormones
4 (20)
Never on hormones 1 (5)
Self-reported adherence to hormones
Excellent 2 (10)
Very good 7 (35)
Good 2 (10)
Fair 1 (5)
Poor 0 (0)
Very poor 0 (0)
Not applicable 5 (25)
Did not respond 3 (15)
a Participants were permitted to choose more than one race/ethnicity;
therefore, total percentage is more than 100
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women have identification documents that list their birth name
and birth sex, but they expect that clinic staff will address
them by their preferred name and female pronouns. Focus
group participants discussed the importance of clinics
documenting their preferred name and pronoun in their med-
ical charts so that they are not called for their appointment by a
male name or pronoun.
“I go by [female name], but my ID still says [male
name]. With me looking like I do, if they call me [male
name] in front of the other patients I might just walk
out.” (Focus group participant)
Access to transition-related healthcare, specifically hor-
mones, from their HIV provider was also cited as an important
facilitator of engagement in HIV care. A few participants
mentioned that it was important that their HIV care provider
was supportive of additional gender affirming procedures the
patient was interested in pursuing or, alternatively, choosing
not to pursue.
“I don't know why they couldn't handle it. All I know
is—she asked me—she was doing a physical exam on
me of the full body and she was just like, why haven't
you had this sex change yet? Like I wasn't a person yet.”
(White interview participant, 39)
Focus group participants also emphasized the benefits of
integrating HIV care and hormone therapy to make these
services more accessible and integrated. One focus group
participant described how she switched her HIV care provider
because the HIV clinic was not familiar with transgender care.
When she switched to a doctor that was more familiar with
proper hormone dosages, she learned that she was previously
prescribed a dose that was too high, which caused the erratic
mood swings she had been experiencing.
Control over One's Body/Medication Regimen
Participants reported feeling that they needed to be in charge
of their medication regimen and described strong feelings of
protectiveness and ownership over their bodies. This was
often related to experiences that occurred for some partici-
pants early in their transition when they felt they had to take
control of their own transition process and make decisions
about hormones without the support of an informed provider.
All participants in the individual interviews reported that they
felt they had to educate themselves about hormones and that
they learned most of what they know from the Internet and
from other transgender women in their community. Many
interview participants described themselves as the primary
decision maker when it comes to their HIV care, whether they
were fully engaged in care or not.
“I do an off and on thing myself, which I know, it's not
recommended. It's a personal choice. But, usually when
it gets to a scary position, when T-cells are too low, or
the viral load is too high, then I start taking mymedicine
again and bringing it back.” (Focus group participant)
HIV-Related Stigma Affects Decisions About Testing
and Care-Seeking Behavior
Concerns About Confidentiality
While access to peer navigation and transgender staff at ser-
vice agencies were reported as important at other stages of the
HIV treatment continuum, at the testing stage, the presence of
transgender peers raised concerns about confidentiality. Par-
ticipants expressed concern that their results may not be held
in confidence if they had an HIV test counselor who was also
part of the transgender community, and this was especially
important for those who reported that they were engaged in
sex work when they received their diagnosis. Focus group
participants also described not wanting to access HIV care at
agencies known for providing such services because they
feared being seen entering or leaving the building or running
into people they knew. Many individual interview participants
reported that prior to their diagnosis, they avoided HIV testing
due to concerns about confidentiality and HIV stigma, which
resulted in delays in diagnosis.
“Someone telling your business like that, you know,
with me having psych issues as well as being HIV
positive, that could send me in a downward spiral until
I want to kill myself or do some harm to myself.”
(African-American interview participant, 39)
Fatalism and Avoidance
Some participants reported that they knew they were at high
risk for HIV and felt that their infection was inevitable. This
was compounded for African-American participants due to
the high rates of HIV associated with both their race and
gender. Some participants described negative experiences in
the healthcare system in the past due to transphobia and thus
were reticent to test and then receive a stigmatized diagnosis
that would require them to access additional healthcare. Four
participants reported that they were diagnosed in mandatory
HIV testing sites due to avoidance of public testing sites, and
one was diagnosed in a housing facility.
“I got arrested and in [that state], if you get arrested for
prostitution or any type of sex crime, it's mandatory that
you take an HIV test, and basically…I was handcuffed
and forced to take an HIV test, and strapped down
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because I refused.” (African-American interview
participant, age 48)
Reduction of HIV-Related Stigma Over Time
A few interview participants as well as participants in the
focus groups discussed the perception that because HIV is so
prevalent in the transgender community, and especially the
African-American transgender community, they are much less
concerned about confidentiality than when they were first
diagnosed. They indicated that as they adapted to their diag-
nosis over the years, learned more about the epidemic, and
received support from HIV+ peers, they were more comfort-
able living openly as an HIV-positive person. In fact, a few of
the participants in both the individual interviews and focus
groups discussed being actively involved in speaking and
volunteering efforts on behalf of the HIV+ transgender com-
munity. They described the rewards of being a role model to
younger transgender women who may be early in their treat-
ment process and struggling to adjust to their diagnosis and
participating in HIV-related and transgender activism.
“Now that I'm clean and sober, I'm definitely on the right
path. I'm proactive and I'm outspoken, and I'm an activ-
ist for HIV and AIDS. I'm an activist for transgender
rights, you know, as a transgender woman, I should be
afforded every right that someone else is afforded. But I
know I'm not.” (African-American interview
participant, 54)
Competing Priorities Are Barriers to Antiretroviral Therapy
Initiation and Adherence
Prioritizing Transition-Related Care
When participants described being in medical care but not
HIV care, it was always in relation to receiving hormones
from a provider. Hormones were often described as a primary
motivator for participants to seek medical care, and other
types of care-seeking behavior were usually described in
relation to their transition. Focus group participants described
how, especially early in their transition, they prioritized
transition-related medical care over their HIV care. If forced
to choose (due to time, money, transportation issues, etc.)
between attending an appointment to receive their hormones
or an appointment with their HIV care provider, they would
choose to get their hormones first. Fears about drug interac-
tions between hormones and HIV medications led some par-
ticipants to forego antiretroviral therapy in favor of staying on
hormones. This seemed to be especially true when they were
early in their transition and believed that antiretroviral therapy
would slow down the desirable effects of hormones.
“I got so many appointments, I got to go to different
pharmacies for mymeds. I make sure I get my hormones
though cuz I gotta stay on track.” (Focus group
participant)
Participants reported that this was less common for them as
they got older, were further along in their transition, and
became better informed about the importance of antiretroviral
therapy. Most of the HIV providers that participants saw early
in their transition were perceived as lacking knowledge about
hormone therapy and were thus not well informed about
possible interactions between hormones and antiretroviral
therapy. However, focus group participants expressed appre-
ciation that there are now more providers in the San Francisco
Bay Area who are knowledgeable, able to provide both hor-
mones and antiretroviral therapy to their patients, and can
answer questions.
One interview participant (African-American, 38) de-
scribed intense frustration early in her HIV treatment over
her HIV care provider withholding hormones because she was
having unexplained side effects when she began taking anti-
retroviral therapy. When she switched providers, it was dis-
covered that she had a sulfa allergy that meant the antiretro-
viral therapy regimen she was on was contraindicated. She
was able to resume her hormone regimen under this new
provider but expressed ongoing resentment that this situation
delayed progression in her transition.
A few interview participants reported that having primary
care providers withhold hormones until their CD4+ cell count
had increased encouraged them to be more adherent to their
antiretroviral therapy regimen so they could resume hormone
treatment. However, other participants reported that if their
provider refused to prescribe hormones they would get them
from somewhere else, such as a different clinic, the street, or
the Internet, indicating that withholding hormones to increase
antiretroviral therapy adherence may have dangerous unin-
tended consequences. Focus group participants discussed the
perception that earlier on in their transition, they were more
likely to seek hormones without a prescription, but currently,
it is relatively easy to get legitimately prescribed hormones in
the San Francisco Bay Area.
Life Instability
Almost all participants reported that, especially when they
were early in their transition and/or recently diagnosed, they
experienced significant instability in their day-to-day lives,
such as the unpredictability of their housing situation, health,
income, food sources, and personal safety. This led to the
prioritization of concerns they felt were more pressing than
HIV care and contributed to difficulty managing the complex
medication regimens and simply forgetting to take their med-
ication. Those in the focus groups particularly emphasized
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that it was hard for them to manage complex pill regimens and
the need to travel to several pharmacies for their medications.
One interview participant described how the complexity and
demands of her daily life often interfere with her ability to
remember to take her medications, “Sometimes I mean to take
them but I don't take them because I forget.” (White interview
participant, age 39)
Some participants noted that the time and energy it took to
navigate complicated systems of care did not seem worth it to
them when they were making money by engaging in sex work.
The lifestyle of sex workers also precluded waking up early in
the day for appointmentswhen they had been up lateworking the
night before.
“[I am not currently using any of the services] because they
cut back on a lot…you standing in line to get some
services, you know, and it's not even anything compared
to what you can really make yourself on the street or
wherever. You know, so it's a waste of time.” (African-
American, 39)
Drug and Alcohol Use
Many women reported using drugs and alcohol to cope with
transphobia and/or avoid dealing with the reality of their diagno-
sis, and many cited substance use as having interfered with their
engagement in care and adherence to medications. A few
discussed the importance of their recovery from drug and alcohol
use and described themselves as currently “clean and sober.”
“[When I receivedmy diagnosis] I went off the deep end
and just went on a rampage and I was getting high
because I never was really an alcohol drinker so mine
was crank. It took 11 years for me to get myself together,
to finally hit rock bottom two or three times.” (African-
American interview participant, age 46)
Participants in the focus groups discussed their frustration
that culturally competent substance abuse treatment was not
readily available, and treatment programs that segregate pa-
tients by gender alienate transgender people. The discussion
focused on their experiences trying to access appropriate treat-
ment. They discussed the fact that even when they were per-
mitted to attend women's substance abuse treatment support
groups, their issues were often so different and the women in
the group so resistant to their presence that it was very difficult
to stay, let alone receive the benefits of support from the group.
“I personally feel that it's hard to concentrate on my
recovery when I have to protect myself from things that
people are saying to me. If there was another substance
abuse program that would only focus on trans people, it
would be great.” (Focus group participant)
Unmet Service Needs Are Barriers to Optimal Engagement
in Care
Housing
Housing was the number one service priority indicated in the
focus groups, followed by medical services, mental health
services, oral health services, substance abuse treatment, and
peer support. Focus group participants discussed their percep-
tion that housing for those living with HIV is temporary, and
that there were few low-income housing options available to
them. They also expressed the need for transitional housing
post-incarceration and a desire for trans-specific housing to
protect them from the transphobia they often encounter from
other residents. HIV-specific housing came with concerns
about confidentiality.
“Discrimination is a big barrier in obtaining housing…
especially if you've never worked… People see you
dressed and think ‘Oh, hooker’. I'm a church girl and I
do everything I'm supposed to do…but I can't get a job
and I can't get housing.” (Focus group participant)
Social Support
About half of the interview participants described pro-
found isolation, particularly early in their transition and/
or when they were first diagnosed, often attributed to
early family rejection and loss of community when they
transitioned. Many focus group participants described
some connection to other transgender women in the
community who they relied on for various forms of
support, including housing, financial support, informa-
tion about transition-related issues (e.g., hormones,
dress), and guidance related to engaging in sex work.
However, they reported that when they received their
HIV diagnosis, they often did not feel able to rely on
this same network for support related to their status.
They feared the ramifications of HIV-related stigma,
including possible loss of confidentiality and rejection
by potential sex partners.
“I don't have friends. I'm a loner. I have acquaintances. I
have people that I choose to talk to about certain things
and share. I have maybe one person that I can trust, you
know.” (White interview participant, age 39)
Some interview participants reported being close to at least
one of their family members and a few described having at
least one close friend at the time of their diagnosis. Having at
least one supportive person to whom they felt they could
safely disclose their diagnosis seemed to serve as a facilitator
to accessing treatment earlier in the disease process. Focus
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group participants discussed the importance of peer support
when accessing and staying engaged in care. In contrast to
their fears about confidentiality when they were first diag-
nosed, they noted that once they were engaged in care, ser-
vices such as peer navigation were useful and important.
Focus group participants also expressed a desire for support
groups led by transgender facilitators, and African-American
focus group participants in particular discussed their prefer-
ence for ethnicity-specific support groups when available.
“There's nothing for the African American transgenders,
specifically. If they do anything that's for the Black
population they want to open it up to the men. The
Black gay men….we need specifics, we need Black
transgenders leading groups for us…[peers who are]
working at these agencies.” (Focus group participant)
“We need to sustain our existence here in San Francisco
which is geared more for White gay men. We're not
White gay men. ” (Focus group participant)
Mental Health Services
About half of the interview participants reported currently
using or having used some form of mental health treatment,
including psychotropic medications. Focus group participants
discussed the need for more readily available mental health
services aside from psychotropic medications. One focus
group discussion of this issue was centered on the perception
that medications to address their mental health problems were
more readily available than therapy, which participants
viewed as a problem.
“I don't take medicine for my mental health but I do like
to talk to someone. The thing is that right now I don't
have that option. I have to write my name in a waiting
list right now. I have to wait between 1 to 1 years before
I get a therapist.” (Focus group participant)
“We as Black trans women don't want to address mental
health because we think it's an ugly thing. But yet, we
transition and we still have anxiety and we still have
PTSD; we still have domestic violence issues; we still
have all that. But yet, it's not being addressed. We're so
busy addressing the hormones and the trans thing and
the HIV that we're leaving out everything else.We're not
dealing with the total package, the total person.”
(African-American interview participant, age 49)
Discussion
Transgender women living with HIV face culturally unique
and substantial challenges to adhering to HIV care and
treatment regimens, such as limited access to and avoidance
of healthcare due to stigma and past negative experiences,
prioritization of gender-related healthcare, and concerns about
adverse interactions between antiretroviral therapy and hor-
mone therapy. Issues that affect other marginalized popula-
tions, such as mental health issues, substance use, and poverty,
were reported as barriers to care among transgender women as
well, but our participants described additional transgender-
specific barriers as a result of transphobia and needs for gender
affirmation and transition-related healthcare. This finding cor-
roborates and expands upon the growing literature that docu-
ments the associations between access to gender affirmation
and improved quality of life, mental health, and self-care
behaviors [29, 39–42].
To better understand the observed disparities in health
outcomes experienced by transgender women living with
HIV, the transgender-specific findings will be the focus of
the discussion here. Furthermore, the majority of our partici-
pants were African-American. This is reflective of the HIV
epidemic among transgender women, and the perspectives of
those who are African-American are predominantly reflected
in our findings. From an intersectional perspective, while our
sample was fairly homogenous in terms of other social vari-
ables (i.e., SES, age), it is important to consider the multipli-
cative impact of race and racism in the lives, social context,
and healthcare experiences of transgender women of color in
our sample.
Gender Affirmation in HIV Care Increases Engagement
and Retention
Gender affirmation was of paramount importance to partici-
pants at every stage of the HIVengagement in care continuum.
Our theoretical model integrating the Gender Affirmation
Model and the Model of Health Care Empowerment clarifies
how experiencing gender affirmation in healthcare settings
may represent a necessary precondition for achieving
healthcare empowerment for many transgender women. Gen-
der affirming healthcare includes interactions with supportive
providers who are knowledgeable about transgender health
and affirming of their gender (i.e., being addressed by the
proper name and pronoun, having supportive interactions in
discussions related to their transgender status), as well as
access to transition-related healthcare (i.e., hormones and/or
surgery). For our participants, transgender sensitivity and
knowledge on the part of providers and clinics were a crucial
barrier when absent and a powerful facilitator when present.
Negative experiences can result in avoidance of healthcare
settings altogether [43–45]. Our findings corroborate other
studies that have reported that when transgender women do
seek healthcare, patients' trust in their provider is compro-
mised when they encounter insensitivity and low levels of
knowledge [46]. Diminished trust subsequently affected
ann. behav. med. (2014) 47:5–16 13
participants' decisions to initiate antiretroviral therapy as well
as their adherence behaviors. When a provider has low levels
of sensitivity and/or knowledge of transgender-specific
healthcare, patients may assume they must make their
healthcare decisions without the support of an informed
provider. For our participants, this led to delayed initi-
ation of antiretroviral therapy, taking drug “holidays,”
and impaired patient–provider communication. As de-
scribed by our theoretical model, gender affirming
healthcare supported engagement and retention in HIV
care among transgender women by increasing patient–
provider trust, fostering positive interactions, and
supporting a collaborative relationship.
Currently, few formal medical education programs
include transgender-specific medical care in their train-
ing of providers [47]. Training providers to conduct
thorough yet respectful health assessments, including
mental health and sexual health, and the creation of
safe clinic spaces will help build trust and rapport with
transgender patients. For example, intake forms should
permit patients to self-identify as transgender, records
should identify their preferred name and pronoun, and
this documentation should be handled as sensitive and
confidential health information. Efforts are currently un-
derway to allow for the identification of transgender
patients using electronic medical records [48] and guide-
lines are available [49].
Integration of Hormone Therapy and Antiretroviral Therapy
in Primary Care Settings
Transgender women living with HIV are often juggling a
variety of demands on their time and energy due to trauma,
addiction, and the deleterious effects of transphobia in their
day-to-day lives. Once they initiated antiretroviral therapy, our
participants often experienced barriers to integrating the reg-
imens into their daily lives. This substantiates our team's
previous quantitative findings that transgender women report-
ed significantly lower self-efficacy in this area than non-
transgender people [50]. Our participants reported that one
method for starting to address this barrier is the integration of
hormone therapy and antiretroviral therapy in HIV primary
care settings, a strategy that has been employed successfully
and recommended by primary care clinics that serve transgen-
der patients [51–53]. Seeing the same provider (or at the very
least, being seen at the same clinic) for both hormones and
antiretroviral therapy made it easier for our participants to
manage their appointments and medications, increased the
likelihood that they kept their appointments due to their high
level of motivation to adhere to their hormone regimen, and
increased trust in their provider. Several resources are available
to guide the provision of hormones for primary care providers
who are new to treating transgender patients [54, 55].
Meeting Transgender Women's Service Needs
Our participants reported that they often feel most comfortable
with outreach and program staff who are also transgender.
However, when testing for HIV and in the stage of early
diagnosis, confidentiality was of extreme importance. The
need for peer support and the need for assurance of confiden-
tiality should be carefully balanced. Concern about HIV-
related stigma among our participants decreased as they de-
scribed becoming more comfortable with their diagnosis over
time. This was especially true for our African-American par-
ticipants who reported that they perceived HIV to be so
pervasive in their communities that HIV-related stigma was
not of much concern, particularly after they had lived with the
diagnosis for many years.
Transgender staff who already have established relation-
ships with the community that the program seeks to serve can
be indispensable in terms of engagement and retention. Our
participants reported placing a great deal of trust in the rec-
ommendations of their peers in terms of where to seek cultur-
ally competent services. In addition, our participants reported
that transgender staff who have personal experience with
many of the same issues that clients face can offer unparalleled
support, guidance, and mentorship. Transgender staff who are
openly living with HIV can model disclosure about status to
help reduce stigma and can serve as an invaluable resource in
peer navigation programs.
Our participants reported that when seeking social services,
they preferred transgender-specific services when possible,
but at minimum wanted reassurance that the services they
sought would be transgender friendly. Programs such as a
transgender-specific portal to a larger health clinic, use of peer
health navigators, and holding transgender-specific clinic
hours are models that have been successful [51]. Our
African-American participants further preferred ethnicity-
specific services whenever possible. They reported the per-
ception that HIV services tend to be geared toward White gay
men and felt that even those HIV-related services that were
geared toward African-Americans tended to then cater to gay
men. In addition, services that increase social support and
build community may help to reduce HIV-related stigma and
support transgender women in coping with life stressors relat-
ed to transphobia.
Theoretical Model: Gender Affirming Care as Powerful
Facilitator of Healthcare Empowerment
Based on these findings, we propose a theoretical model that
integrates the Models of Gender Affirmation and Health Care
Empowerment [29, 32]. Getting one's needs for gender affir-
mation met may serve as a pathway to healthcare empower-
ment for transgender women. Our participants reported that
when their gender affirmation needs are met, they are more
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likely to be engaged and collaborative in their healthcare due
to increased trust in their provider and more committed and
informed due to increased motivation to engage in self-care
behaviors. This model may be useful in the development of
interventions, policies, and future research aimed at optimiz-
ing HIV treatment engagement and retention among transgen-
der women.
Limitations
The current findings are drawn from a convenience sample of
transgender women living with HIV in the San Francisco Bay
Area, and most participants were either already connected to
our research through a cross-sectional survey or were con-
nected to an agency. These findings may not generalize to
transgender women who are more isolated or significantly
different from our sample in other ways. Our sample had a
mean age of 49; younger transgender women may report
different barriers to care. The interviewers who conducted
the individual interviews were both male, while the focus
group facilitators were both transgender women. This may
have affected some participants' ability to be as open and
honest as possible in their responses, and face-to-face inter-
views may increase participants' motivation to provide social-
ly desirable responses. Some aspects of the interview were
retrospective, and recall about early experiences may not be as
accurate as recall about more recent experiences. All of our
individual interview participants were receiving HIV care
services in the San Francisco Bay Area at the time of data
collection. As this area is comparatively rich in resources
dedicated to serving the transgender community, transgender
women living with HIV in other areas may experience addi-
tional or more intense barriers to care that are not reflected
here. Our methods did not permit a quantitative assessment of
interrater reliability [56, 57]. Thus, the analysis conducted by
the primary coder may have influenced the analysis of the
secondary coder. We compensated for this possibility by hav-
ing the secondary coder provide dissenting viewpoints and/or
expanding upon the analysis of the primary coder.
Conclusion
Engagement and retention of transgender women in HIV care
and treatment will be optimized by services that are gender
affirming and integrate transition-related healthcare needs.
Such interventions must fully attend to the social, economic,
and psychological context of transgender women's lives and
address the multiple barriers to healthcare engagement, treat-
ment adherence, and empowerment that serve to create, main-
tain, and deepen HIV-related health disparities among trans-
gender women living with HIV.
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